Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Charles Aswell

Internal Medicine Ville Platte, LA Medical Doctor

NPI 1801842141 CMS profile 353965

503 Jack Miller Rd, Suite A, Ville Platte, LA 70586

Open in the dashboard

General payments

$3,927

318 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Charles Aswell of Ville Platte, LA is reported in the CMS Open Payments database as having received $3,927 across 318 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $221 13
2021 General $1,335 106
2020 General $769 58
2019 General $1,603 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Aswell
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Charles Aswell were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Charles Aswell Internal Medicine median Middle half National median
2019 $1,603 $159 $48–$570 $163
2020 $769 $119 $33–$402 $114
2021 $1,335 $135 $37–$521 $132
2022 $221 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. GlaxoSmithKline, LLC. $432 38 payments
  2. Novo Nordisk Inc $430 42 payments
  3. Novartis Pharmaceuticals Corporation $403 27 payments
  4. Janssen Pharmaceuticals, Inc $347 29 payments
  5. AstraZeneca Pharmaceuticals LP $287 15 payments
  6. Mylan Specialty L.P. $252 18 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $220 20 payments
  8. Lilly USA, LLC $212 17 payments
  9. Merck Sharp & Dohme Corporation $206 16 payments
  10. AbbVie, Inc. $200 18 payments
  11. Other $936 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,914 315 payments
  2. Education $14 3 payments
Products named General payments · program years 2019–2022
  1. Ozempic $406 39 payments
  2. ENTRESTO $403 27 payments
  3. TRELEGY ELLIPTA $371 31 payments
  4. XARELTO $342 28 payments
  5. RYBELSUS $280 25 payments
  6. XIFAXAN $220 20 payments
  7. FARXIGA $192 11 payments
  8. Perforomist $186 14 payments
  9. Yupelri $177 13 payments
  10. TRULICITY $169 13 payments
  11. Other $2,522 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

192

Median for Internal Medicine: 777

Drug cost

$3,191

Median for Internal Medicine: $73,373

Branded share of claims

28.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 25 $547
Pantoprazole Sodium Generic 29 $543
Ipratropium-Albuterol Ipratropium/Albuterol Sulfate Brand 16 $496
Atorvastatin Calcium Generic 26 $413
Escitalopram Oxalate Generic 20 $303
Thioridazine Hcl Generic 25 $303
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 13 $232
Sucralfate Generic 12 $185
Furosemide Generic 13 $85
Lithium Carbonate Generic 13 $85

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record